Epidermal growth factor receptor (egfr) antibodies market analysis report

Transparency Market Research

Epidermal Growth Factor Receptor Single User License: (EGFR) Antibodies Market - Global USD 4315.5  Flat 10% Discount!!

Industry Analysis, Size, Share,  Free Customization as per your requirement Growth, Trends and Forecast 2015  You will get Custom Report at Syndicated Report price 2023 

Transparency Market Research State Tower, 90, State Street, Suite 700.

Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.co m

Report will be delivered with in 15-20 working days

Request Sample

Buy Now

REPORT DESCRIPTION

Transparency Market Research Reports incorporated a definite business overview and investigation inclines on "Epidermal Growth Factor Receptor (EGFR) Antibodies Market". This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure.

The epidermal growth factor receptor (EGFR) is defined as a transmembrane tyrosine kinase receptor involved in the survival and proliferation of the cancerous cells. Any kind of mutations affecting these EFGR receptors or activity could results in cancer.

Mutations lead to over-expresion resulting in large number of cancer, including lung cancer, anal cancer and glioblastoma multiforme. EGFR receptors are the first molecule target against which monoclonal antibodies (mAb) have been designed for cancer treatment. These monoclonal antibodies are sometimes also referred as EGFR antibodies. EGFR antibodies market can be segmented on the basis of the major antibodies which are used against EGFR receptors which include: •Cetuximab •Panitumumab •Nimotuzumab Cetuximab (erbitux) and panitumumab (vecitibix) are the most preferred biosimilar EGFR antibodies which are used for treatment of cancer. These antibodies have demonstrated efficacy in the treatment of colorectal cancer as single agents and in combination with conventional chemotherapy. Since the US Food and Drug Administration (FDA) had approved cetuximab in 2003 and panitumumab in 2006, EGFR antibodies have become primary step of treatment algorithms for colorectal cancer.

However, nimotuzumab is a humanized monoclonal antibody that as of 2014 is recognized under orphan drugs status in the U.S. and the European Union for the treatment of glioma. This drug has also achieved marketing approval in India and China for squamaus cell carcinoma of the neck and head, and is currently undergoing numerous clinical trials.

Browse Full Report with TOC: http://www.transparencymarketresearch.com/epidermal-growth-factor-receptor-antibodiesmarket.html

Additionally, many market players and research institutions are performing research activities on development of the biosuperior EGFR antibodies against cancerous cells. The most common biosuperior EGFR antibodies include engineered EGFR antibodies, Bi- and Multi-specific EGFR antibodies and EGFR antibody drug conjugates. As for instance, Hoffmann-La Roche is performing a phase 1b study of MPDL3280A (and engineered antibody) in combination with Tarceva in patients suffering from non-small cell lung cancer. Such extensive research and development activities associated with the development of EGFR antibodies biosuperiors is the major factor which is driving this market. However, the high cost associated with research activities and sunk cost involved in R&D activities restrains the EGFR antibodies market.

Moreover, the increasing incidence of cancer worldwide is also demanding for the more effective treatment methods, which is encouraging the researchers to develop EGFR antibodies. According to World Health Organization (WHO), cancer was the leading cause of death in 2012, accounting for 8.2 million deaths worldwide. Lung, liver, colorectal, stomach and breast cancers were responsible for most of the deaths every year. Statistics also revealed that breast cancer incidence had risen by more than 20% in 2012 from 2009, while breast cancer mortality rate has increased by 14%. Due to harsh lifestyle, excessive intake of alcohol and smoking habits, the incidence of cancer is increasing rapidly worldwide, especially in developed economies of North America and Europe. Increasing morbidity and mortality rate among the cancer patients is fuelling the demand for EGFR antibodies, hence driving the market.

Some of the market players which are actively contributing towards EGFR antibodies market include Amgen, Inc., Eisai, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer, Inc., Biocon Ltd., Takeda Pharmaceutical Company, Ltd. and Immunogen, Inc. Request for Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7325 This research report analyzes this market on the basis of its market segments, major geographies, and current market trends.

This report provides comprehensive analysis of •Market growth drivers •Factors limiting market growth •Current market trends

•Market structure •Market projections for upcoming years This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report •This report provides pin-point analysis for changing competitive dynamics •It provides a forward looking perspective on different factors driving or restraining market growth •It provides a six-year forecast assessed on the basis of how the market is predicted to grow •It helps in understanding the key product segments and their future •It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors •It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments •It provides distinctive graphics and exemplified SWOT analysis of major market segments

About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/